Category: Pediatric MS

Cognitive Behavioral Therapy for Pediatric Headache and Migraine: Why to Prescribe and What New Research Is Critical for Advancing Integrated Biobehavioral Care

↓ Full text Kroon Van Diest AM, et al. Headache. 2018. Show full citation Abstract PURPOSE OF REVIEW: To highlight current…

Stuart Schlossman

MS in a Child Considerably Affects Quality of Life for Family, Study Reports

SEPTEMBER 10, 2018 BY JANET STEWART, MSC Parents of children with pediatric-onset multiple sclerosis (MS) report a lower overall quality of life…

Stuart Schlossman

New Drug Could Help Kids With MS

By Dennis Thompson HealthDay Reporter WEDNESDAY, Sept. 12, 2018 (HealthDay News) — Researchers say the first drug for children with multiple…

Stuart Schlossman

Gilenya More Effective Than Avonex in Lowering Relapse Rates, New Lesions in Children with Relapsing MS, Phase 3 Trial Shows

SEPTEMBER 17, 2018 BY PATRICIA INACIO, PHD   IN ALEXA, NEWS. Two years of treatment with oral Gilenya (fingolimod) significantly reduced the rate of relapses…

Stuart Schlossman

What Do We Know About Pediatric MS?

Prevalence Although MS occurs most commonly in adults, it is also diagnosed in children and adolescents. Estimates suggest that 8,000-10,000 children…

Stuart Schlossman

Trial of fingolimod vs interferon beta-1a in pediatric multiple sclerosis

New England Journal of Medicine — Chitnis T, et al. | September 14, 2018 In this phase 3 trial, researchers compared fingolimod with interferon…

Stuart Schlossman

Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis

Sep 13, 2018 Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures…

Stuart Schlossman

MS in Children

MS is usually thought of as an adult condition, but children and teenagers can also develop it Last updated: 18th…

Stuart Schlossman

More on Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

In May 2018, Novartis announced FDA approval of Gilenya® as the first disease-modifying therapy for the treatment of children and adolescents 10…

Stuart Schlossman

Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI

First Published June 1, 2018 Abstract Objective: To determine the frequency of cortical lesions (CLs) in patients with pediatric-onset multiple sclerosis…

Stuart Schlossman

Categories

Latest Blog Posts